244 related articles for article (PubMed ID: 33954898)
1. Sequential chemo-hypofractionated RT versus concurrent standard CRT for locally advanced NSCLC: GRADE recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
Merlotti A; Bruni A; Borghetti P; Ramella S; Scotti V; Trovò M; Chiari R; Lohr F; Ricardi U; Bria E; Pappagallo GL; D'Angelillo RM; Arcangeli S
Radiol Med; 2021 Aug; 126(8):1117-1128. PubMed ID: 33954898
[TBL] [Abstract][Full Text] [Related]
2. Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up.
Parisi E; Genestreti G; Sarnelli A; Ghigi G; Arpa D; Burgio MA; Gavelli G; Rossi A; Scarpi E; Monti M; Tesei A; Polico R; Romeo A
Radiat Oncol; 2019 Jun; 14(1):112. PubMed ID: 31234868
[TBL] [Abstract][Full Text] [Related]
3. A pilot trial of consolidation bevacizumab after hypo-fractionated concurrent chemoradiotherapy in patients with unresectable locally advanced non-squamous non-small-cell lung cancer.
Huo L; Chu C; Jiang X; Zheng S; Zhang P; Zhou R; Chen N; Guo J; Qiu B; Liu H
Cancer Med; 2023 Sep; 12(17):17638-17647. PubMed ID: 37537968
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Results of A Prospective Phase II Study (GASTO-1049).
Zhou R; Qiu B; Xiong M; Liu Y; Peng K; Luo Y; Wang D; Liu F; Chen N; Guo J; Zhang J; Huang X; Rong Y; Liu H
Int J Radiat Oncol Biol Phys; 2023 Oct; 117(2):387-399. PubMed ID: 37100160
[TBL] [Abstract][Full Text] [Related]
5. [Outcome of concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer patients].
Liu L; Wang X; Ji Z; Wang J; Bi N; Hui Z; Lyu J; Liang J; Zhou Z; Feng Q; Chen D; Zhang H; Xiao Z; Yin W; Wang L
Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):863-7. PubMed ID: 26887520
[TBL] [Abstract][Full Text] [Related]
6. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center.
Shrimali RK; Nallathambi C; Saha A; Das A; Prasath S; Mahata A; Arun B; Mallick I; Achari R; Dabkara D; Thambudorai R; Chatterjee S
Indian J Cancer; 2018; 55(2):125-133. PubMed ID: 30604722
[TBL] [Abstract][Full Text] [Related]
7. Hypofractionated radiation therapy in the management of locally advanced NSCLC: a narrative review of the literature on behalf of the Italian Association of Radiation Oncology (AIRO)-Lung Working Group.
Parisi G; Mazzola R; Ciammella P; Timon G; Fozza A; Franceschini D; Navarria F; Bruni A; Perna M; Giaj-Levra N; Alongi F; Scotti V; Trovo M
Radiol Med; 2019 Feb; 124(2):136-144. PubMed ID: 30368721
[TBL] [Abstract][Full Text] [Related]
8. Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
Bozorgmehr F; Chung I; Christopoulos P; Krisam J; Schneider MA; Brückner L; Mueller DW; Thomas M; Rieken S
BMC Cancer; 2020 Aug; 20(1):806. PubMed ID: 32842974
[TBL] [Abstract][Full Text] [Related]
9. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.
Dieleman E; van der Woude L; van Os R; van Bockel L; Coremans I; van Es C; De Jaeger K; Knol HP; Kolff W; Koppe F; Pomp J; Reymen B; Schinagl D; Spoelstra F; Tissing-Tan C; van der Voort van Zyp N; van der Wel A; Wijsman R; Dielwart M; Wiegman E; Damhuis R; Belderbos J
Clin Lung Cancer; 2023 Mar; 24(2):130-136. PubMed ID: 36572596
[TBL] [Abstract][Full Text] [Related]
10. Concurrent chemoradiotherapy versus radiotherapy alone after induction chemoimmunotherapy for stage III NSCLC patients who did not undergo surgery: a single institution retrospective study.
Guan S; Ren K; Zhang X; Yan M; Li X; Zhao L
Radiat Oncol; 2023 Jul; 18(1):122. PubMed ID: 37491257
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy.
Vrankar M; Stanic K
Radiol Oncol; 2018 Feb; 52(3):281-288. PubMed ID: 30210037
[TBL] [Abstract][Full Text] [Related]
12. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.
Byhardt RW; Scott C; Sause WT; Emami B; Komaki R; Fisher B; Lee JS; Lawton C
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):469-78. PubMed ID: 9806503
[TBL] [Abstract][Full Text] [Related]
13. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.
Chang JY; Verma V; Li M; Zhang W; Komaki R; Lu C; Allen PK; Liao Z; Welsh J; Lin SH; Gomez D; Jeter M; O'Reilly M; Zhu RX; Zhang X; Li H; Mohan R; Heymach JV; Vaporciyan AA; Hahn S; Cox JD
JAMA Oncol; 2017 Aug; 3(8):e172032. PubMed ID: 28727865
[TBL] [Abstract][Full Text] [Related]
14. Sequential chemoradiotherapy with accelerated hypofractionated radiotherapy compared to concurrent chemoradiotherapy with standard radiotherapy for locally advanced non-small cell lung cancer.
Zhu ZF; Ma HL; Fan M; Bao Y; Zhuang TT; Chen M; Jiang GL; Fu XL
Technol Cancer Res Treat; 2014 Jun; 13(3):269-75. PubMed ID: 24066952
[TBL] [Abstract][Full Text] [Related]
15. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
Rajappa S; Sharma S; Prasad K
Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
[TBL] [Abstract][Full Text] [Related]
16. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
[TBL] [Abstract][Full Text] [Related]
17. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö
Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741
[TBL] [Abstract][Full Text] [Related]
18. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
19. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).
Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S
Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556
[TBL] [Abstract][Full Text] [Related]
20. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
